Welcome to our dedicated page for Elutia news (Ticker: ELUT), a resource for investors and traders seeking the latest updates and insights on Elutia stock.
Elutia Inc. (Nasdaq: ELUT) is a regenerative medicine company that develops drug-eluting biomatrix products to improve compatibility between implantable medical devices and patients. The ELUT news feed on Stock Titan aggregates company-issued updates, regulatory disclosures and other coverage so readers can follow how Elutia’s biomatrix platform and business strategy are evolving over time.
Recent Elutia news has focused on its NXT-41 and NXT-41x biomatrix programs in plastic and reconstructive surgery, particularly breast reconstruction. Press releases describe NXT-41 as a novel base matrix and NXT-41x as an antibiotic-eluting version built on a platform that was clinically and commercially validated with EluPro, which the company sold to Boston Scientific as part of its BioEnvelope business divestiture. News items also discuss expected regulatory milestones for these products and the company’s intention to use proceeds from asset sales to fund development and commercialization.
Investors and observers can also find coverage of financial results and capital structure changes, including quarterly earnings press releases, the impact of the $88 million BioEnvelope sale, repayment of secured debt, and updates on cash balances described in preliminary financial announcements. Additional news includes information on board changes, conference presentations, and published clinical data on biologic envelopes used with cardiac implantable electronic devices, which illustrate how Elutia’s biomatrix technology has performed in prior applications.
Because Elutia operates in a regulated medical and biotech environment, its news often touches on clinical evidence, FDA-related expectations, litigation updates and Nasdaq listing matters, such as the November 2025 notice regarding minimum bid price compliance. Bookmarking this ELUT news page provides a single location to review Elutia’s ongoing disclosures about its drug-eluting biomatrix platform, strategic transactions and progress in targeted surgical markets.
Elutia (Nasdaq: ELUT), a leader in drug-eluting biomatrix products, announced that Dr. Randy Mills, President and CEO, will present at the Emerging Growth Conference on July 18, 2024, at 12:35 p.m. ET (9:35 a.m. PT). The event will be webcast live, and interested institutional investors can schedule one-on-one meetings with Elutia's management by contacting IR@elutia.com. This presentation will provide insights into Elutia's current projects and future plans, making it a important event for stakeholders and potential investors.
Elutia has announced a $13.26 million registered direct offering, agreeing to sell 3,175,000 shares of its Class A common stock at $3.40 per share, and 725,000 prefunded warrants at $3.399 per warrant. The prefunded warrants are immediately exercisable at an exercise price of $0.001 per warrant. The gross proceeds, expected to be $13.26 million, will be used for working capital and general corporate purposes. The offering, managed by Lake Street Capital Markets, is set to close around June 18, 2024, pending customary conditions. The securities are offered under an effective SEC shelf registration statement.
Elutia announced that its Antibiotic-Eluting BioEnvelope, EluPro, has received FDA clearance. This innovative product is designed to protect patients with implantable cardiac devices from complications such as infection, migration, and skin erosion. EluPro is the only biologic solution in the $600 million U.S. implantable electronic device protection market. Additionally, EluPro has been cleared for use with neurostimulators and neuromodulators, opening up an $8 billion market opportunity. The product combines antibiotic therapy with advanced tissue engineering to create a regenerative pocket for the device. Elutia plans to launch EluPro nationwide in the second half of 2024.
Elutia Inc. (Nasdaq: ELUT) will showcase its CanGaroo® BioEnvelope product line at the Heart Rhythm Society's annual meeting. The innovative biologic matrix enhances device stability and patient comfort for cardiac implantable electronic devices. Elutia's management team will be present at the event to demonstrate the product's benefits.
Elutia Inc. (Nasdaq: ELUT) announced its first quarter 2024 results, highlighting a 55% increase in sales for SimpliDerm® and positive progress with FDA interactions for CanGaroo®RM. With a focus on disruptive technology in the pacemaker and defibrillator protection market, Elutia aims to set new standards for patient outcomes. The financial results showcased overall revenue growth, with net sales reaching $6.7 million and a gross margin of 42% on a GAAP basis. Despite a decline in cardiovascular product sales, Elutia remains optimistic about the pending FDA decision for CanGarooRM and the commercial launch expected in the second half of 2024.
Elutia Inc. (Nasdaq: ELUT) will report its first quarter 2024 financial results on May 9, 2024. The company specializes in drug-eluting biomatrix products. A conference call and webcast will be held on the same day.
Summary not available.
Summary not available.
Summary not available.
Summary not available.